Clinical Trials
427 trialsBuMelMCRN001
University Health Network, Toronto
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
University of Southern California
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
Janssen Research & Development, LLC
CARTITUDE-2
Janssen Research & Development, LLC
MonumenTAL-1
Janssen Research & Development, LLC
MajesTEC-2
Janssen Research & Development, LLC
CARTITUDE-5
Janssen Research & Development, LLC
MonumenTAL-2
Janssen Research & Development, LLC
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Janssen Research & Development, LLC
Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
Jiangsu HengRui Medicine Co., Ltd.
IMPACT
University of Utah
A Study of Daratumumab
Janssen Research & Development, LLC
MajesTEC-7
Janssen Research & Development, LLC
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
AbbVie
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC
MagnetisMM15
Pfizer
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Pfizer
CERVINO
AbbVie
MMRC Horizon One: RRMM (MMRC-099)
Multiple Myeloma Research Consortium
MonumenTAL-6
Janssen Research & Development, LLC
Talisman
Janssen Research & Development, LLC
MonumenTAL-8
Janssen Research & Development, LLC
aMMbition
Janssen Research & Development, LLC
A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
National Institutes of Health Clinical Center (CC)
A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma
Johnson & Johnson Private Limited
CARTITUDE-10
Janssen Research & Development, LLC
SCILLA
Odense University Hospital
TRIlogy-4
Janssen Research & Development, LLC
TRIlogy-3
Janssen Research & Development, LLC
TRIlogy-5
Janssen Research & Development, LLC
Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma
The First Affiliated Hospital with Nanjing Medical University
Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation
Stanford University
²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
Fred Hutchinson Cancer Center
Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
National Institutes of Health Clinical Center (CC)
AMYLOCARP
Ramsay Générale de Santé
MajesTEC-4
European Myeloma Network B.V.
LINKER-MGUS1
Regeneron Pharmaceuticals
Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes
PETHEMA Foundation
High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders
University of Arkansas
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
Duke University
FASTER
SCRI Development Innovations, LLC
A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.
A Phase I Study of SHR-3836 in Patients With Multiple Myeloma
Shanghai Hengrui Pharmaceutical Co., Ltd.
Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma
University of Iowa
Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis
Beijing Boren Hospital
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
KRDI in Transplant-Eligible MM
Massachusetts General Hospital